cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity

Stephen T. Ferris, Vivek Durai, Renee Wu, Derek J. Theisen, Jeffrey P. Ward, Michael D. Bern, Jesse T. Davidson, Prachi Bagadia, Tiantian Liu, Carlos G. Briseño, Lijin Li, William E. Gillanders, Gregory F. Wu, Wayne M. Yokoyama, Theresa L. Murphy, Robert D. Schreiber and Kenneth M. Murphy ()
Additional contact information
Stephen T. Ferris: Washington University School of Medicine
Vivek Durai: Washington University School of Medicine
Renee Wu: Washington University School of Medicine
Derek J. Theisen: Washington University School of Medicine
Jeffrey P. Ward: Washington University School of Medicine
Michael D. Bern: Washington University School of Medicine
Jesse T. Davidson: Washington University School of Medicine
Prachi Bagadia: Washington University School of Medicine
Tiantian Liu: Washington University School of Medicine
Carlos G. Briseño: Washington University School of Medicine
Lijin Li: Washington University School of Medicine
William E. Gillanders: Washington University School of Medicine
Gregory F. Wu: Washington University School of Medicine
Wayne M. Yokoyama: Washington University School of Medicine
Theresa L. Murphy: Washington University School of Medicine
Robert D. Schreiber: Washington University School of Medicine
Kenneth M. Murphy: Washington University School of Medicine

Nature, 2020, vol. 584, issue 7822, 624-629

Abstract: Abstract Conventional type 1 dendritic cells (cDC1)1 are thought to perform antigen cross-presentation, which is required to prime CD8+ T cells2,3, whereas cDC2 are specialized for priming CD4+ T cells4,5. CD4+ T cells are also considered to help CD8+ T cell responses through a variety of mechanisms6–11, including a process whereby CD4+ T cells ‘license’ cDC1 for CD8+ T cell priming12. However, this model has not been directly tested in vivo or in the setting of help-dependent tumour rejection. Here we generated an Xcr1Cre mouse strain to evaluate the cellular interactions that mediate tumour rejection in a model requiring CD4+ and CD8+ T cells. As expected, tumour rejection required cDC1 and CD8+ T cell priming required the expression of major histocompatibility class I molecules by cDC1. Unexpectedly, early priming of CD4+ T cells against tumour-derived antigens also required cDC1, and this was not simply because they transport antigens to lymph nodes for processing by cDC2, as selective deletion of major histocompatibility class II molecules in cDC1 also prevented early CD4+ T cell priming. Furthermore, deletion of either major histocompatibility class II or CD40 in cDC1 impaired tumour rejection, consistent with a role for cognate CD4+ T cell interactions and CD40 signalling in cDC1 licensing. Finally, CD40 signalling in cDC1 was critical not only for CD8+ T cell priming, but also for initial CD4+ T cell activation. Thus, in the setting of tumour-derived antigens, cDC1 function as an autonomous platform capable of antigen processing and priming for both CD4+ and CD8+ T cells and of the direct orchestration of their cross-talk that is required for optimal anti-tumour immunity.

Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (6)

Downloads: (external link)
https://www.nature.com/articles/s41586-020-2611-3 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:584:y:2020:i:7822:d:10.1038_s41586-020-2611-3

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-020-2611-3

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().